ClinicalTrials.gg
CompletedNCT03248531Updated Apr 11, 2022Results posted

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

A Phase 2 interventional study of Bimekizumab and Adalimumab in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Completed at 31 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
56th of 139
90 · median 45
Started
2017
with 6 others
Phase 2
61 of 161
11 open now
Registered
25th of 161
by date
Lead sponsor
6 of 161
UCB Biopharma SRL

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 56th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2017, is one of 61 in phase 2, and was the 25th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • Bimekizumab
  • HS
  • Moderate to Severe HS
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects (18 to 70 years of age, inclusive) must have a diagnosis of HS for at least

    1 year prior to Baseline

  • Stable HS for at least 2 months prior to Screening and also at the Baseline Visit
  • Inadequate response to at least a 3-month study of an oral antibiotic for treatment of HS
  • Total abscess and inflammatory nodule count >=3 at the Baseline Visit
  • Subject must agree to daily use (and throughout the entirety of the study) of 1 pre-specified over-the-counter topical antiseptics on their HS lesions
  • Female subjects must be , permanently sterilized or, if of , must be willing to use a highly effective method of up till 20 weeks after last administration of study drug and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose
  • Male subjects must be willing to use a method of contraception when sexually active, up till 20 weeks after the last administration of study medication

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with anti-IL17s or participation in an anti-IL17 study
  • Previously received anti-TNFs
  • Subject requires, or is expected to require, opioid analgesics for any reason (excluding tramadol)
  • Subject received prescription topical therapies for the treatment of HS within 14 days prior to the Baseline Visit
  • Subject received systemic non-biologic therapies for HS with potential therapeutic impact for HS less than 28 days prior to Baseline Visit
  • Draining fistula count >20 at the Baseline Visit
  • Diagnosis of inflammatory conditions other than HS
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.

    Drug: Bimekizumab

  • Active comparator
    Adalimumab

    Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.

    Drug: Adalimumab

  • Placebo comparator
    Placebo

    Subjects will receive several placebo applications to keep the blinding.

    Other: Placebo

Interventions

  • Bimekizumab in different dosages (dose 1 and 2).

    Also known as: UCB4940

  • Adalimumab in different dosages (dose 1, 2 and 3).

    Also known as: Humira®

  • OtherPlacebo

    Placebo will be provided matching Bimekizumab.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

    HiSCR was defined as at least a 50 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining fistula count. Results were based on a Bayesian logistic regression model where the number of responders were assumed to follow a binomial distribution. Participants with missing data at Week 12 were considered as nonresponders in the analysis. Posterior mean response rates and 95% credible intervals in each group are presented.

    Time frame: Week 12

Secondary outcomes

  1. Bimekizumab Plasma Concentration at Day 1 (Prior to First Dose)

    Plasma concentration of Bimekizumab was expressed in nanograms per milliliter (ng/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (75 ng/mL) in calculations of Means and Coefficient of Variations (CVs).

    Time frame: Day 1 (Prior to first dose)

  2. Bimekizumab Plasma Concentration at Week 2

    Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

    Time frame: Week 2

  3. Bimekizumab Plasma Concentration at Week 4

    Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

    Time frame: Week 4

  4. Bimekizumab Plasma Concentration at Week 8

    Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

    Time frame: Week 8

  5. Bimekizumab Plasma Concentration at Week 12

    Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

    Time frame: Week 12

  6. Bimekizumab Plasma Concentration at Week 30

    Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

    Time frame: Week 30

  7. Percentage of Participants With at Least One Adverse Event During the Study

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Screening to Safety Follow-Up (Week 30)

  8. Percentage of Participants With at Least One Adverse Event Categorized by Maximum Severity During the Study

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. To record the intensity of an AE Investigator used the following criteria: Mild: the study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with the usual activities of the study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.

    Time frame: From Screening to Safety Follow-Up (Week 30)

  9. Percentage of Participants With at Least One Serious Adverse Event During the Study

    A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalisation, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above.

    Time frame: From Screening to Safety Follow-Up (Week 30)

  10. Percentage of Participants With at Least One Serious Adverse Event Categorized by Severity During the Study

    A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalization, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above. To record the intensity of an AE Investigator used the following criteria: Mild: study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with usual activities of study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.

    Time frame: From Screening to Safety Follow-Up (Week 30)

  11. Percentage of Participants That Withdrew Due to Adverse Events During the Study

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Screening to Safety Follow-Up (Week 30)

  12. Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)

    Blood pressure was measured in millimeters of mercury (mmHg).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  13. Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)

    Pulse rate was measured in beats per minute (beats/min).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  14. Change From Baseline Until Safety Follow-up Visit in Body Weight

    Body weight was measured in kilograms (kg).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  15. Change From Baseline Until Safety Follow-up Visit in ECG Parameters (ECG Mean Heart Rate)

    Electrocardiogram (ECG) Mean Heart Rate was measured in beats/min.

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  16. Change From Baseline Until Safety Follow-up Visit in ECG Parameters (PR Interval, QRS Duration, QT Interval, QTcF Interval)

    PR Interval, QRS duration, QT interval and QT corrected for heart rate using Fridericia's correction (QTcF) Interval were measured in milliseconds (msec).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  17. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)

    Erythrocytes was measured in number of red blood cells per liter (10\^12/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  18. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)

    Hematocrit was measured in volume percentage (%) of red blood cells in blood.

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  19. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hemoglobin, Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration)

    Hemoglobin, erythrocytes mean corpuscular hemoglobin (HGB) concentration were measured in grams per liter (g/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  20. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))

    Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  21. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)

    Erythrocytes mean corpuscular volume was measured in femtoliters (fL).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  22. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)

    Platelets was measured in number of platelets per liter (10\^9/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  23. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils)

    Leukocytes, basophils, eosinophils, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10\^9/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  24. Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes)

    Basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes were measured in percentages (%).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  25. Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Bicarbonate, Chloride, Potassium, Sodium, Calcium, Magnesium, Urea Nitrogen, Cholesterol, Glucose)

    Bicarbonate, chloride, potassium, sodium, calcium, magnesium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  26. Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin, Urate)

    Creatinine, bilirubin, and urate were measured in micromols per liter (μmol/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  27. Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein High Sensitivity)

    C reactive protein high sensitivity was measured in milligrams per liter (mg/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  28. Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase)

    Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase were measured in units per liter (U/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  29. Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine pH)

    Urine pH was measured on a pH scale.

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  30. Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Albumin)

    Urine albumin was measured in milligrams per liter (mg/L).

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  31. Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Glucose)

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  32. Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Leukocyte Esterase)

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  33. Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Bacteria)

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  34. Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Erythrocytes)

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  35. Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Physical Examination

    Time frame: From Baseline to Safety Follow-Up (Week 30)

  36. Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Day 1

    The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

    Time frame: Day 1

  37. Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 2

    The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

    Time frame: Week 2

  38. Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 4

    The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

    Time frame: Week 4

  39. Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 8

    The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

    Time frame: Week 8

  40. Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 12

    The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

    Time frame: Week 12

  41. Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 30

    The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

    Time frame: Week 30

07

Results

Posted Feb 9, 2022

Participant flow

The study started to enroll patients in September 2017 and concluded in February 2019.

Participant flow — Overall Study
MilestonePlaceboAdalimumabBimekizumab
Started222246
Completed week 12191842
Completed181738
Not completed458
Withdrew: Adverse event001
Withdrew: Lost to follow-up105
Withdrew: Withdrawal by subject332
Withdrew: Sponsor request020

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

HiSCR was defined as at least a 50 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining fistula count. Results were based on a Bayesian logistic regression model where the number of responders were assumed to follow a binomial distribution. Participants with missing data at Week 12 were considered as nonresponders in the analysis. Posterior mean response rates and 95% credible intervals in each group are presented.

Time frame:
Week 12
Reported as:
Mean · Percentage of responders
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
Percentage of respondersPlacebo (PPS)Adalimumab (PPS)Bimekizumab (PPS)
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 1226.1 (13.8 to 40.5)59.5 (44.2 to 73.9)57.3 (42.4 to 71.4)
Statistical analysis
  • Placebo (PPS) vs Bimekizumab (PPS) · Regression, Logistic · Mean posterior difference: 31.2 · 95% CI 11.0 to 50.4
  • Adalimumab (PPS) vs Bimekizumab (PPS) · Regression, Logistic · Mean posterior difference: -2.2 · 60% CI -11.2 to 6.6
  • Placebo (PPS) vs Bimekizumab (PPS) · Regression, Logistic · Pr [diff>0%] (%): 99.8
  • Adalimumab (PPS) vs Bimekizumab (PPS) · Regression, Logistic · Pr[diff > 0%](%): 42.1
SecondaryBimekizumab Plasma Concentration at Day 1 (Prior to First Dose)

Plasma concentration of Bimekizumab was expressed in nanograms per milliliter (ng/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (75 ng/mL) in calculations of Means and Coefficient of Variations (CVs).

Time frame:
Day 1 (Prior to first dose)
Reported as:
Geometric mean · ng/mL
Bimekizumab Plasma Concentration at Day 1 (Prior to First Dose)
ng/mLBimekizumab (PK-PPS)
Bimekizumab Plasma Concentration at Day 1 (Prior to First Dose)NA ± NA
SecondaryBimekizumab Plasma Concentration at Week 2

Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

Time frame:
Week 2
Reported as:
Geometric mean · ng/mL
Bimekizumab Plasma Concentration at Week 2
ng/mLBimekizumab (PK-PPS)
Bimekizumab Plasma Concentration at Week 224086.4 ± 56.4
SecondaryBimekizumab Plasma Concentration at Week 4

Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

Time frame:
Week 4
Reported as:
Geometric mean · ng/mL
Bimekizumab Plasma Concentration at Week 4
ng/mLBimekizumab (PK-PPS)
Bimekizumab Plasma Concentration at Week 426572.6 ± 57.6
SecondaryBimekizumab Plasma Concentration at Week 8

Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

Time frame:
Week 8
Reported as:
Geometric mean · ng/mL
Bimekizumab Plasma Concentration at Week 8
ng/mLBimekizumab (PK-PPS)
Bimekizumab Plasma Concentration at Week 830222.6 ± 54.5
SecondaryBimekizumab Plasma Concentration at Week 12

Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

Time frame:
Week 12
Reported as:
Geometric mean · ng/mL
Bimekizumab Plasma Concentration at Week 12
ng/mLBimekizumab (PK-PPS)
Bimekizumab Plasma Concentration at Week 1225319.0 ± 116.8
SecondaryBimekizumab Plasma Concentration at Week 30

Plasma concentration of Bimekizumab was expressed in ng/mL. Values BLQ were replaced by value of LLOQ/2 (75 ng/mL) in calculations of Means and CVs.

Time frame:
Week 30
Reported as:
Geometric mean · ng/mL
Bimekizumab Plasma Concentration at Week 30
ng/mLBimekizumab (PK-PPS)
Bimekizumab Plasma Concentration at Week 30NA ± NA
SecondaryPercentage of Participants With at Least One Adverse Event During the Study

An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
From Screening to Safety Follow-Up (Week 30)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event During the Study
percentage of participantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Percentage of Participants With at Least One Adverse Event During the Study61.971.471.7
SecondaryPercentage of Participants With at Least One Adverse Event Categorized by Maximum Severity During the Study

An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. To record the intensity of an AE Investigator used the following criteria: Mild: the study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with the usual activities of the study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.

Time frame:
From Screening to Safety Follow-Up (Week 30)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event Categorized by Maximum Severity During the Study
percentage of participantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Mild47.666.763.0
Moderate33.342.939.1
Severe4.89.56.5
SecondaryPercentage of Participants With at Least One Serious Adverse Event During the Study

A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalisation, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above.

Time frame:
From Screening to Safety Follow-Up (Week 30)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Serious Adverse Event During the Study
percentage of participantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Percentage of Participants With at Least One Serious Adverse Event During the Study9.54.84.3
SecondaryPercentage of Participants With at Least One Serious Adverse Event Categorized by Severity During the Study

A serious adverse event (SAE) was any untoward medical occurrence that at any dose: Resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalization, was a congenital anomaly or birth defect, was an infection that required treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may have jeopardised the patients, or may have required medical or surgical intervention to prevent any of the above. To record the intensity of an AE Investigator used the following criteria: Mild: study participant was aware of sign or symptom (syndrome), but it did not interfere with his/her usual activities and/or was of no clinical consequence; Moderate: AE interfered with usual activities of study participant or it was of some clinical consequence; Severe: the study participant was unable to work normally or to carry out his/her usual activities, or the AE was of definite clinical consequence.

Time frame:
From Screening to Safety Follow-Up (Week 30)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Serious Adverse Event Categorized by Severity During the Study
percentage of participantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Mild04.80
Moderate4.800
Severe4.84.84.3
SecondaryPercentage of Participants That Withdrew Due to Adverse Events During the Study

An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
From Screening to Safety Follow-Up (Week 30)
Reported as:
Number · percentage of participants
Percentage of Participants That Withdrew Due to Adverse Events During the Study
percentage of participantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Percentage of Participants That Withdrew Due to Adverse Events During the Study002.2
SecondaryChange From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)

Blood pressure was measured in millimeters of mercury (mmHg).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · mmHg
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)
mmHgPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Systolic Blood Pressure-2.9 ± 14.84.5 ± 14.5-0.4 ± 13.8
Diastolic Blood Pressure-1.8 ± 8.4-0.6 ± 9.1-2.2 ± 11.2
SecondaryChange From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)

Pulse rate was measured in beats per minute (beats/min).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · beats/min
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)
beats/minPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)-1.4 ± 10.2-1.8 ± 10.8-1.6 ± 10.8
SecondaryChange From Baseline Until Safety Follow-up Visit in Body Weight

Body weight was measured in kilograms (kg).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · kg
Change From Baseline Until Safety Follow-up Visit in Body Weight
kgPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Body Weight0.90 ± 7.391.82 ± 3.940.42 ± 6.89
SecondaryChange From Baseline Until Safety Follow-up Visit in ECG Parameters (ECG Mean Heart Rate)

Electrocardiogram (ECG) Mean Heart Rate was measured in beats/min.

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · beats/min
Change From Baseline Until Safety Follow-up Visit in ECG Parameters (ECG Mean Heart Rate)
beats/minPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in ECG Parameters (ECG Mean Heart Rate)-2.1 ± 12.4-2.1 ± 11.11.5 ± 10.1
SecondaryChange From Baseline Until Safety Follow-up Visit in ECG Parameters (PR Interval, QRS Duration, QT Interval, QTcF Interval)

PR Interval, QRS duration, QT interval and QT corrected for heart rate using Fridericia's correction (QTcF) Interval were measured in milliseconds (msec).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · msec
Change From Baseline Until Safety Follow-up Visit in ECG Parameters (PR Interval, QRS Duration, QT Interval, QTcF Interval)
msecPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
PR Interval0.8 ± 18.82.4 ± 10.53.6 ± 18.7
QRS duration-0.3 ± 7.10.2 ± 5.20.6 ± 7.4
QT interval4.8 ± 20.24.2 ± 26.71.8 ± 27.7
QTcF Interval-11.7 ± 49.9-0.3 ± 14.42.4 ± 12.7
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)

Erythrocytes was measured in number of red blood cells per liter (10\^12/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · 10^12 red blood cells per liter
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)
10^12 red blood cells per literPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)0.144 ± 0.349-0.151 ± 0.416-0.013 ± 0.274
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)

Hematocrit was measured in volume percentage (%) of red blood cells in blood.

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · volume % of red blood cells
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)
volume % of red blood cellsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)2.01 ± 2.83-0.81 ± 4.300.39 ± 2.69
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hemoglobin, Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration)

Hemoglobin, erythrocytes mean corpuscular hemoglobin (HGB) concentration were measured in grams per liter (g/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · g/L
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hemoglobin, Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration)
g/LPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Hemoglobin5.3 ± 11.6-3.7 ± 11.61.1 ± 7.6
Erythrocytes mean corpuscular HGB-1.4 ± 16.2-2.6 ± 13.4-0.2 ± 13.2
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))

Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · picograms (pg)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))
picograms (pg)Placebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))0.29 ± 0.760.21 ± 0.780.30 ± 0.99
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)

Erythrocytes mean corpuscular volume was measured in femtoliters (fL).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · femtoliters (fL)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)
femtoliters (fL)Placebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)1.49 ± 2.951.36 ± 3.211.04 ± 4.03
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)

Platelets was measured in number of platelets per liter (10\^9/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · 10^9 platelets per liter
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)
10^9 platelets per literPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)-17.4 ± 38.72.3 ± 61.6-19.2 ± 51.4
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils)

Leukocytes, basophils, eosinophils, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10\^9/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · 10^9 white blood cells per liter
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils)
10^9 white blood cells per literPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Leukocytes-0.281 ± 2.621-0.114 ± 2.997-0.122 ± 2.308
Basophils0.009 ± 0.0260.033 ± 0.0770.015 ± 0.048
Eosinophils0.007 ± 0.077-0.012 ± 0.1000.002 ± 0.056
Lymphocytes0.029 ± 0.8120.241 ± 0.6820.038 ± 0.570
Monocytes0.072 ± 0.420-0.032 ± 0.3220.060 ± 0.192
Neutrophils-0.396 ± 2.076-0.341 ± 2.460-0.240 ± 2.234
SecondaryChange From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes)

Basophils/leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes were measured in percentages (%).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · % of white blood cells per leukocytes
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes)
% of white blood cells per leukocytesPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Basophils/leukocytes0.13 ± 0.230.42 ± 0.930.13 ± 0.65
Eosinophils/leukocytes-0.12 ± 1.92-0.03 ± 1.090.12 ± 1.12
Lymphocytes/leukocytes1.43 ± 5.472.04 ± 6.732.04 ± 8.07
Monocytes/leukocytes0.49 ± 4.35-0.20 ± 2.791.00 ± 2.17
Neutrophils/leukocytes-1.93 ± 6.84-2.24 ± 7.50-3.29 ± 9.55
SecondaryChange From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Bicarbonate, Chloride, Potassium, Sodium, Calcium, Magnesium, Urea Nitrogen, Cholesterol, Glucose)

Bicarbonate, chloride, potassium, sodium, calcium, magnesium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · mmol/L
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Bicarbonate, Chloride, Potassium, Sodium, Calcium, Magnesium, Urea Nitrogen, Cholesterol, Glucose)
mmol/LPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Bicarbonate-0.1 ± 2.10.7 ± 2.80.6 ± 2.3
Chloride0.9 ± 1.51.3 ± 2.40.1 ± 2.2
Potassium-0.13 ± 0.79-0.09 ± 0.370.03 ± 0.41
Sodium0.4 ± 1.50.4 ± 1.60.1 ± 2.2
Calcium0.027 ± 0.0650.008 ± 0.1440.067 ± 0.095
Magnesium-0.029 ± 0.087-0.027 ± 0.052-0.009 ± 0.081
Urea nitrogen0.00 ± 1.46-0.43 ± 1.370.29 ± 1.79
Cholesterol-0.311 ± 0.667-0.177 ± 0.6340.157 ± 0.585
Glucose1.049 ± 1.8350.436 ± 2.9900.439 ± 2.212
SecondaryChange From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin, Urate)

Creatinine, bilirubin, and urate were measured in micromols per liter (μmol/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · μmol/L
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin, Urate)
μmol/LPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Creatinine-1.73 ± 9.92-1.72 ± 9.043.84 ± 9.22
Bilirubin0.17 ± 3.48-1.38 ± 3.040.18 ± 4.35
Urate8.7 ± 52.2-8.9 ± 50.51.5 ± 43.1
SecondaryChange From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein High Sensitivity)

C reactive protein high sensitivity was measured in milligrams per liter (mg/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · mg/L
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein High Sensitivity)
mg/LPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein High Sensitivity)-2.801 ± 16.851-4.865 ± 21.863-2.810 ± 10.853
SecondaryChange From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase)

Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase were measured in units per liter (U/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · U/L
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase)
U/LPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Alanine aminotransferase-3.3 ± 8.3-3.6 ± 9.83.6 ± 23.8
Alkaline phosphatase-2.0 ± 12.2-2.4 ± 13.5-3.4 ± 11.6
Aspartate aminotransferase-0.6 ± 3.6-1.0 ± 5.82.0 ± 13.3
Gamma glutamyl transferase-2.0 ± 9.51.8 ± 14.22.3 ± 10.1
Lactate dehydrogenase-17.0 ± 29.9-16.3 ± 35.6-12.8 ± 61.8
SecondaryChange From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine pH)

Urine pH was measured on a pH scale.

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · pH
Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine pH)
pHPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine pH)-0.43 ± 0.98-0.25 ± 0.55-0.03 ± 0.69
SecondaryChange From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Albumin)

Urine albumin was measured in milligrams per liter (mg/L).

Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Mean · mg/L
Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Albumin)
mg/LPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Albumin)50.80 ± 211.30-28.25 ± 121.290.49 ± 19.92
SecondaryNumber of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Glucose)
Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Count of participants · Participants
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Glucose)
ParticipantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Baseline Low - Week 30 Low000
Baseline Low - Week 30 Normal000
Baseline Low - Week 30 High000
Baseline Normal - Week 30 Low000
Baseline Normal - Week 30 Normal121428
Baseline Normal - Week 30 High110
Baseline High - Week 30 Low000
Baseline High - Week 30 Normal011
Baseline High - Week 30 High102
SecondaryNumber of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Leukocyte Esterase)
Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Count of participants · Participants
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Leukocyte Esterase)
ParticipantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Baseline Low - Week 30 Low000
Baseline Low - Week 30 Normal000
Baseline Low - Week 30 High000
Baseline Normal - Week 30 Low000
Baseline Normal - Week 30 Normal8919
Baseline Normal - Week 30 High206
Baseline High - Week 30 Low000
Baseline High - Week 30 Normal236
Baseline High - Week 30 High240
SecondaryNumber of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Bacteria)
Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Count of participants · Participants
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Bacteria)
ParticipantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Baseline Low - Week 30 Low000
Baseline Low - Week 30 Normal000
Baseline Low - Week 30 High000
Baseline Normal - Week 30 Low000
Baseline Normal - Week 30 Normal000
Baseline Normal - Week 30 High000
Baseline High - Week 30 Low000
Baseline High - Week 30 Normal000
Baseline High - Week 30 High362
SecondaryNumber of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Erythrocytes)
Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Count of participants · Participants
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (Urine Erythrocytes)
ParticipantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Baseline Low - Week 30 Low000
Baseline Low - Week 30 Normal000
Baseline Low - Week 30 High000
Baseline Normal - Week 30 Low000
Baseline Normal - Week 30 Normal101
Baseline Normal - Week 30 High000
Baseline High - Week 30 Low000
Baseline High - Week 30 Normal000
Baseline High - Week 30 High210
SecondaryNumber of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Physical Examination
Time frame:
From Baseline to Safety Follow-Up (Week 30)
Reported as:
Count of participants · Participants
Number of Participants Who Shifted From Baseline Until Safety Follow-up Visit in Physical Examination
ParticipantsPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Baseline Normal - Week 30 Normal141528
Baseline Normal - Week 30 Abnormal125
Baseline Abnormal - Week 30 Normal111
Baseline Abnormal - Week 30 Abnormal214
SecondaryPercentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Day 1

The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Day 1
percentage of participantsBimekizumab (PK-PPS)
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Day 14.3
SecondaryPercentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 2

The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 2
percentage of participantsBimekizumab (PK-PPS)
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 24.4
SecondaryPercentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 4

The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 4
percentage of participantsBimekizumab (PK-PPS)
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 44.3
SecondaryPercentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 8

The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 8
percentage of participantsBimekizumab (PK-PPS)
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 80
SecondaryPercentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 12

The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 12
percentage of participantsBimekizumab (PK-PPS)
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 129.5
SecondaryPercentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 30

The overall status of a study participant was 'Positive' if at any post-Baseline visit the result was positive. Percentages were based on the number of study participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 30
percentage of participantsBimekizumab (PK-PPS)
Percentage of Participants With Positive Bimekizumab Anti-drug Antibody (ADA) Concentration at Week 3013.9

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from Baseline (Day 1) until the Safety Follow-Up Visit (Week 30). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (SS)0/21 (0%)2/21 (9.5%)5/21 (23.8%)
Adalimumab (SS)0/21 (0%)1/21 (4.8%)12/21 (57.1%)
Bimekizumab (SS)0/46 (0%)2/46 (4.3%)21/46 (45.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
Myocardial infarctionCardiac disorders1/210/210/46
HeadacheNervous system disorders1/210/210/46
DizzinessNervous system disorders1/210/210/46
HypoaesthesiaNervous system disorders1/210/210/46
HidradenitisSkin and subcutaneous tissue disorders0/211/210/46
AnaemiaBlood and lymphatic system disorders0/210/211/46
EmpyemaInfections and infestations0/210/211/46
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo (SS)Adalimumab (SS)Bimekizumab (SS)
HidradenitisSkin and subcutaneous tissue disorders3/216/218/46
InfluenzaInfections and infestations0/213/210/46
HeadacheNervous system disorders3/210/213/46
FatigueGeneral disorders0/212/214/46
PyrexiaGeneral disorders0/212/211/46
Injection site pruritusGeneral disorders0/212/212/46
Upper respiratory tract infectionInfections and infestations0/212/212/46
ArthralgiaMusculoskeletal and connective tissue disorders1/212/211/46
DiarrhoeaGastrointestinal disorders0/211/213/46
NauseaGastrointestinal disorders0/211/213/46

Baseline characteristics

Baseline Characteristics refer to the Randomized Set (RS) which consisted of all study participants randomized into the study.

Age, Categorical
Age, Categorical(Participants)PlaceboAdalimumabBimekizumabTotal Title
<=18 years0022
Between 18 and 65 years21224487
>=65 years1001
Age, Continuous
Age, Continuous(years)PlaceboAdalimumabBimekizumabTotal Title
Mean40.7 ± 12.531.0 ± 9.237.4 ± 11.936.6 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumabBimekizumabTotal Title
Female15183063
Male741627
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAdalimumabBimekizumabTotal Title
American Indian or Alaskan Native1001
Asian1304
Black or African American651021
White12143561
Other or Mixed2013
08

Study locations

31 sites
  • Hs0001 121
    Los Angeles, California 90033, United States
  • Hs0001 119
    Coral Gables, Florida 33134, United States
  • Hs0001 111
    Orange, Florida 32073, United States
  • Hs0001 117
    Tampa, Florida 33624, United States
  • Hs0001 112
    Sandy Springs, Georgia 30328, United States
  • Hs0001 113
    Boston, Massachusetts 02215, United States
  • Hs0001 115
    Las Vegas, Nevada 89074, United States
  • Hs0001 126
    Manhasset, New York 11030, United States
  • Hs0001 125
    Chapel Hill, North Carolina 27599, United States
  • Hs0001 123
    Hershey, Pennsylvania 17033, United States
  • Hs0001 120
    Nashville, Tennessee 37215, United States
  • Hs0001 103
    East Melbourne, Australia
  • Hs0001 101
    Fremantle, Australia
  • Hs0001 104
    Saint Leonards, Australia
  • Hs0001 100
    Westmead, Australia
  • Hs0001 102
    Woolloongabba, Australia
  • Hs0001 203
    Brussels, Belgium
  • Hs0001 202
    Liège, Belgium
  • Hs0001 300
    Copenhagen, Denmark
  • Hs0001 408
    Berlin, Germany
  • Hs0001 405
    Bochum, Germany
  • Hs0001 407
    Darmstadt, Germany
  • Hs0001 400
    Dessau, Germany
  • Hs0001 404
    Erlangen, Germany
  • Hs0001 406
    Würzburg, Germany
  • Hs0001 503
    Athens, Greece
  • Hs0001 701
    Harstad, Norway
  • Hs0001 700
    Tromsø, Norway
  • Hs0001 901
    Moscow, Russian Federation
  • Hs0001 903
    Saint Petersburg, Russian Federation
  • Hs0001 900
    Yaroslavl, Russian Federation
09

References and documents

Publications

  • Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S, Baeten D, Ionescu L, Zouboulis CC, Shaw S. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. JAMA Dermatol. 2021 Nov 1;157(11):1279-1288. doi: 10.1001/jamadermatol.2021.2905. Erratum In: JAMA Dermatol. 2021 Nov 1;157(11):1384. doi: 10.1001/jamadermatol.2021.4442. PubMed 34406364 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2018, 14 months.

Results were first posted in Feb 2022, 3 years 2 months after primary completion. A results delay was requested in Nov 2019.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 14 months is close to that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2017
First posted
Aug 14, 2017
StartActual
Sep 22, 2017
Primary completionActual
Nov 23, 2018
CompletionActual
Feb 21, 2019
Results delay requested
Nov 22, 2019
Results first posted
Feb 9, 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03248531
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Aug 14, 2017
Start date
Sep 22, 2017
Primary completion
Nov 23, 2018
Completion
Feb 21, 2019
Results posted
Feb 9, 2022
Last update
Apr 11, 2022

Study contacts

UCB Cares
study director · +1-844-599-2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion